Nanobiotix SA (NANO.PA) stock: key figures, P/E, revenue and dividend
Health Care · France · ISIN FR0011341205
Nanobiotix SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | -11.61 m EUR | 29.64 m EUR |
| Gross profit | 0.00 EUR | 29.64 m EUR |
| Operating income | -68.26 m EUR | -10.82 m EUR |
| EBIT | -68.00 m EUR | – |
| Net income | -68.00 m EUR | -23.96 m EUR |
| Diluted EPS – continuing operations | -1.44 EUR | -0.50 EUR |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
More stocks
- CompuGroup Medical SE & Co KgaA (COP.DE)
- Hub Group, Inc. (HUBG)
- Jinfu Technology Co Ltd (003018.SZ)
- Opple Lighting Co Ltd (603515.SS)
- China Bohai Bank Co Ltd (9668.HK)
- Googol Technology Co Ltd Class A (301510.SZ)
- Borregaard ASA (BRG.OL)
- Guangdong Feinan Resources Recycling Co Ltd (301500.SZ)
- Athens Water Supply and Sewerage Company SA (EYDAP.AT)
- Zip Co Ltd (ZIP.AX)
- Friedrich Vorwerk Group (VH2.DE)
- Senior PLC (SNR.L)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.